376 0 Kommentare Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend - Seite 2

3. PREFERRED STOCK DIVIDEND: On March 25, 2015 the Company paid a 10% stock dividend to shareholders of record on March 10, 2015. This dividend was paid in Regen BioPharma's Series A Preferred Shares. These shares are not convertible into common. The Company anticipates obtaining a symbol specific to the Series A Preferred Shares at the earliest possible date, with the goal of developing a public market for these shares.

4. SCIENTIFIC ADVISOR BOARD EXPANSION (SAB): The Company is currently expanding the SAB to facilitate relationships that will assist in the Company's research. New SAB members are expected to help with protocol development and study design, as well as theoretical approaches to the Company's research areas. The Company is currently in the process of updating its website so that information on new SAB members may be viewed by the public.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.